Welcome to the website of the Dutch Childhood Oncology Group - Early Clinical Trial Consortium (DCOG-ECTC). The DCOG-ECTC is a consortium which aims at implementing early phase clinical trials in children with cancer. The DCOG-ECTC is one of the collaborating partners in ITCC, an European based consortium to promote the clinical evaluation of new anti-cancer compounds in children with cancer. The consortium consists of 47 European Pediatric Oncology Departments with expertise in conducting early phase trials in children and adolescents, and 9 European research laboratories.
This website has been developed for investigators and their study teams participating in DCOG-ECTC studies. The main goal is to provide the participating sites with all relevant study-related information, and to introduce a tool for the participating sites to implement and perform the DCOG-ECTC early clinical trials.
All participating study teams will be invited by DCOG-ECTC and will receive an account, which you need to log in.
Please use internet Explorer version 8 or higher, or Firefox version 14, or the latest versions of Chrome or Safari. Make sure that Flash player is enabled otherwise the website will not work properly.
A user manual for invited users is available. If you have any question or in case you encounter problems please let us know.
Please check the registration procedure in the protocol. Use the links below to register and/or randomize a patient for a specific trial in ALEA. If your center has been initiated the account details for randomization have been provided to you.
Please follow the link below to work on the electronic case report forms (eCRF) of the study you are participating in.
The links below are only accessible for the Central Datamanagers.
Trial Office DCOG-ECTC
Follow the link below to go to the sharepoint environment of the NFU.
NECTAR: closed per November 9, 2015November 09, 2015
The TACL Study Committee and the TACL Operations Center has announced the following:
Effective November 9, 2015, the NECTAR study (TACL T2008-002/ITCC-033) is closed to accrual.
Due to slow accrual rate, continued enrollment will not be pursued.
The Study Committee thanks all participating TACL and ITCC sites for your efforts to support study completion.
ITCC 021: Bortezomib in childhood relapsed ALL: CLOSED for new patient inclusionsOctober 22, 2014
Please allow me to inform you that the inclusion of patients in the Bortezomib pediatric ALL (ITCC 021) ‘A feasibility and phase II study in childhood relapsed acute lymphoblastic leukemia’ is definitively CLOSED for new patient inclusions.
The target number of evaluable patients has been reached.
We will work towards the final report and paper, and will require your assistance to attain a clean dataset.
The investigator files will be required to be updated. We will inform you of the pending issues separately and inform you about the close out procedures as soon as possible.